1. Home
  2. SNDA vs URGN Comparison

SNDA vs URGN Comparison

Compare SNDA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDA
  • URGN
  • Stock Information
  • Founded
  • SNDA 1990
  • URGN 2004
  • Country
  • SNDA United States
  • URGN United States
  • Employees
  • SNDA N/A
  • URGN N/A
  • Industry
  • SNDA Hospital/Nursing Management
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNDA Health Care
  • URGN Health Care
  • Exchange
  • SNDA Nasdaq
  • URGN Nasdaq
  • Market Cap
  • SNDA 462.3M
  • URGN 465.9M
  • IPO Year
  • SNDA 1997
  • URGN 2017
  • Fundamental
  • Price
  • SNDA $23.79
  • URGN $10.82
  • Analyst Decision
  • SNDA Hold
  • URGN Strong Buy
  • Analyst Count
  • SNDA 1
  • URGN 6
  • Target Price
  • SNDA $25.00
  • URGN $40.75
  • AVG Volume (30 Days)
  • SNDA 29.5K
  • URGN 395.0K
  • Earning Date
  • SNDA 03-17-2025
  • URGN 03-10-2025
  • Dividend Yield
  • SNDA N/A
  • URGN N/A
  • EPS Growth
  • SNDA N/A
  • URGN N/A
  • EPS
  • SNDA N/A
  • URGN N/A
  • Revenue
  • SNDA $253,196,000.00
  • URGN $90,398,000.00
  • Revenue This Year
  • SNDA $14.30
  • URGN $43.60
  • Revenue Next Year
  • SNDA $9.72
  • URGN $103.77
  • P/E Ratio
  • SNDA N/A
  • URGN N/A
  • Revenue Growth
  • SNDA 10.95
  • URGN 9.29
  • 52 Week Low
  • SNDA $18.58
  • URGN $9.03
  • 52 Week High
  • SNDA $34.26
  • URGN $20.70
  • Technical
  • Relative Strength Index (RSI)
  • SNDA 46.79
  • URGN 58.14
  • Support Level
  • SNDA $23.41
  • URGN $9.11
  • Resistance Level
  • SNDA $25.04
  • URGN $10.43
  • Average True Range (ATR)
  • SNDA 1.24
  • URGN 0.63
  • MACD
  • SNDA -0.15
  • URGN 0.10
  • Stochastic Oscillator
  • SNDA 43.67
  • URGN 88.66

About SNDA Sonida Senior Living Inc.

Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: